JUSTIN PETRIE: Open Payments
NPI 1164816443 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,080 in 114 payments from 17 companies in 2025. Trend: 2023 $664 · 2024 $1,343 · 2025 $2,080
Food & beverage: $2,080
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $284 |
| Neurocrine BioSciences, Inc. | 13 | $282 |
| ABBVIE INC. | 17 | $275 |
| Otsuka America Pharmaceutical, Inc. | 14 | $213 |
| Alkermes, Inc. | 9 | $202 |
| Teva Pharmaceuticals USA, Inc. | 8 | $178 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $109 |
| Vanda Pharmaceuticals Inc. | 2 | $73 |
| Almatica Pharma LLC | 4 | $66 |
Products named: COBENFY, INGREZZA, VRAYLAR, ARISTADA, REXULTI, CAPLYTA, AUSTEDO XR, TRINTELLIX.
Industry payments across NV — which companies pay providers there.
